NEW YORK, NY – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Whitney Ijem has joined the firm as a Director in a planned expansion of the Healthcare Research team. Ms. Ijem is focusing on the coverage of Biotech companies, working closely with the firm’s growing therapeutics team.
Ms. Ijem joins Guggenheim from Tourbillon Capital, where she was a healthcare analyst focused on companies across the therapeutics space. Prior to Tourbillon, she was a biotech analyst in the J.P. Morgan Equity Research Healthcare group. Before joining J.P. Morgan, Ms. Ijem was a biotech analyst at Canaccord Genuity. She began her career at Arcoda Capital.
“We are excited to have Whitney join Guggenheim,” said Stefano Natella, Director of Equity Research. “She is a great addition to our healthcare equity research team, and she represents our continued commitment to invest in our healthcare research platform. We look forward to her continued success at Guggenheim.”
In the last 12 months, Guggenheim has significantly expanded its therapeutics research team, which now includes Michael Schmidt, Adnan Butt, Seamus Fernandez, and Etzer Darout.
Ms. Ijem received her M.S. in Biomaterials Science from New York University and her B.S. in Biomedical Engineering from Washington University in St. Louis. She is based in Guggenheim’s New York office.
About Guggenheim Securities
Guggenheim Securities is the investment banking and capital markets business of Guggenheim Partners, a global investment and advisory firm. Guggenheim Securities offers services that fall into four broad categories: Advisory, Financing, Sales and Trading, and Research. Guggenheim Securities is headquartered in New York, with additional offices in Chicago, Boston, Atlanta, Los Angeles, San Francisco, and Houston. For more information, please contact us at GSinfo@GuggenheimPartners.com or 212.518.9200.
About Guggenheim Partners
Guggenheim Partners is a global investment and advisory firm with more than $305 billion in assets under management. Across our three primary businesses of investment management, investment banking, and insurance services, we have a track record of delivering results through innovative solutions. With over 2,400 professionals based in more than 25 offices around the world, our commitment is to advance the strategic interests of our clients and to deliver long-term results with excellence and integrity. We invite you to learn more about our expertise and values by visiting GuggenheimPartners.com and following us on Twitter at twitter.com/guggenheimptnrs.
1Assets under management are as of 03.31.2018 and include consulting services for clients whose assets are valued at approximately $66bn. In April 2018, Guggenheim Investments closed the sale of the firm’s Exchange Traded Fund (“ETF”) business representing $38.6bn in assets under management, which will be reflected in the June 30, 2018 assets under management.